VETmAb Biosciences Reports Positive Canine Inflammatory Enteropathy Proof-of-Concept Results
The company said 77.8% of dogs in the VMB-C001a group were treatment successes, compared with 30.0% in the comparison group.
The company said 77.8% of dogs in the VMB-C001a group were treatment successes, compared with 30.0% in the comparison group.